Adaptive Biotechnologies Corporation - notizie pubblicate 188 - letture 6.244
ADAPTIVE BIOTECHNOLOGIES CORPORATION
Statement of Changes in Beneficial Ownership - Form 4
Form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchange commission washingt ...
ADAPTIVE BIOTECHNOLOGIES CORPORATION
Adaptive Biotechnologies Reports Second Quarter 2023 Financial Results - Form 8-K
Adaptive biotechnologies reports second quarter 2023 financial results seattle, aug. 02, 2023 (globe newswire) - adaptive biotechnologies corporation ("adaptive biotechnologie ...
ADAPTIVE BIOTECHNOLOGIES CORPORATION
Quarterly Report for Quarter Ending June 30, 2023 (Form 10-Q)
United states securities and exchange commission washington, dc 20549 form 10-q (mark one) ☒ quarterly report pursuant to section 13 or 15(d) of the securities exchange act of 19 ...
ADAPTIVE BIOTECHNOLOGIES CORPORATION
Adaptive Biotechnologies Q2 2023 Earnings Presentation
Second quarter 2023 earnings conference call safe harbor this presentation has been prepared by adaptive biotechnologies corporation ("we," "us," "our,&quo ...
ADAPTIVE BIOTECHNOLOGIES CORPORATION
Adaptive Biotechnologies Reports Second Quarter 2023 Financial Results
Pdf version seattle, aug. 02, 2023 (globe newswire) -- adaptive biotechnologies corporation ("adaptive biotechnologies") (nasdaq: adpt), a commercial stage biotechnology ...
ADAPTIVE BIOTECHNOLOGIES CORPORATION
Adaptive Biotechnologies to Report Second Quarter Financial Results on August 2, 2023
Pdf version seattle, july 10, 2023 (globe newswire) -- adaptive biotechnologies corporation ("adaptive biotechnologies") (nasdaq: adpt), a commercial stage biotechnology ...
ADAPTIVE BIOTECHNOLOGIES CORPORATION
Failure to Satisfy Listing Rule - Form 8-K
8-k united states securities and exchange commission washington, d.c. 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 date of r ...
ADAPTIVE BIOTECHNOLOGIES CORPORATION
Statement of Changes in Beneficial Ownership - Form 4
Form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchange commission washingt ...
ADAPTIVE BIOTECHNOLOGIES CORPORATION
Statement of Changes in Beneficial Ownership - Form 4
Form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchange commission washingt ...
ADAPTIVE BIOTECHNOLOGIES CORPORATION
Management Change - Form 8-K
8-k united states securities and exchange commission washington, d.c. 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 date of r ...
ADAPTIVE BIOTECHNOLOGIES CORPORATION
Statement of Changes in Beneficial Ownership - Form 4
Form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchange commission washingt ...
ADAPTIVE BIOTECHNOLOGIES CORPORATION
Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay’s Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer
Pdf version new data emphasizes the value of mrd testing in predicting survival outcomes and informing the personalized treatment of patients with hematologic cancers clonoseq cont ...
ADAPTIVE BIOTECHNOLOGIES CORPORATION
Additional Proxy Soliciting Materials - Form DEFA14A
United states securities and exchange commission washington, d.c. 20549 schedule 14a proxy statement pursuant to section 14(a) of the securities exchange act of 1934 filed by the r ...
ADAPTIVE BIOTECHNOLOGIES CORPORATION
Adaptive Biotechnologies to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
Pdf version seattle, may 12, 2023 (globe newswire) -- adaptive biotechnologies corporation ("adaptive biotechnologies") (nasdaq: adpt), a commercial stage biotechnology c ...
ADAPTIVE BIOTECHNOLOGIES CORPORATION
Adaptive Biotechnologies Announces FDA Acceptance of Genentech's Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology - Form 8-K
Adaptive biotechnologies announces fda acceptance of genentech's investigational new drug application for the first neoantigen-directed t-cell therapy product in oncology - the t-c ...
Sei un professionista?
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti